NCT00291577 - Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

February 28, 2009

Conditions

Breast Neoplasms

Interventions

DRUG

Sunitinib (Sutent)

Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision

DRUG

Taxotere

Taxotere 75 mg/m2 iv, once every 3 weeks

Trial Locations (3)

1000

Pfizer Investigational Site, Brussels

20133

Pfizer Investigational Site, Milan

171 76

Pfizer Investigational Site, Stockholm